ALDH3A2

Across TCGA pan-cancer cohorts, ALDH3A2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ALDH3A2 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ALDH3A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ALDH3A2 expression acts as an unfavorable survival marker.

HNSC, LUSC, and SKCM are the cancer types where ALDH3A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.144	0.663	<.001	30	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	12	view →
SKCM	DFS	Median	III,IV	0.040	0.597	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ALDH3A2–HNSC (DFS)

Open the HNSC breakdown →